NDC 0942-6305 Cpda-1

Anticoagulant Citrate Phosphate Dextrose Adenine

NDC Product Code 0942-6305

NDC 0942-6305-03

Package Description: 63 mL in 1 BAG

NDC Product Information

Cpda-1 with NDC 0942-6305 is a a human prescription drug product labeled by Fenwal, Inc.. The generic name of Cpda-1 is anticoagulant citrate phosphate dextrose adenine. The product's dosage form is solution and is administered via intravenous form.

Labeler Name: Fenwal, Inc.

Dosage Form: Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Cpda-1 Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

  • DEXTROSE MONOHYDRATE 2 g/63mL
  • TRISODIUM CITRATE DIHYDRATE 1.66 g/63mL
  • ANHYDROUS CITRIC ACID 188 mg/63mL
  • SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 140 mg/63mL
  • ADENINE 17.3 mg/63mL

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intravenous - Administration within or into a vein or veins.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Acidifying Activity - [MoA] (Mechanism of Action)
  • Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
  • Anti-coagulant - [EPC] (Established Pharmacologic Class)
  • Decreased Coagulation Factor Activity - [PE] (Physiologic Effect)
  • Calcium Chelating Activity - [MoA] (Mechanism of Action)
  • Acidifying Activity - [MoA] (Mechanism of Action)
  • Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
  • Anti-coagulant - [EPC] (Established Pharmacologic Class)
  • Decreased Coagulation Factor Activity - [PE] (Physiologic Effect)
  • Calcium Chelating Activity - [MoA] (Mechanism of Action)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Fenwal, Inc.
Labeler Code: 0942
FDA Application Number: BN770420 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: NDA - A product marketed under an approved New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 03-01-2007 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2019 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions. Values = ‘Y’ or ‘N’.

* Please review the disclaimer below.

Cpda-1 Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index

Instructions For Blood Collection Using Anticoagulant Citrate Phosphate Dextrose Adenine Solution, Usp (Cpda-1) Blood-Pack™ Units

  • Rx onlyContains Sample Diversion System for the collection of whole blood samples for laboratory testing.Also includes the DONORCARE™ Needle Guard.Instructions for UseCollection Procedure:Use aseptic technique.Notes: •If Sample Diversion System is not used, donor samples may be collected using an alternate method following standard procedures. •Nominal tubing dimensions of product are 0.118" inner diameter x 0.025" wall thickness.Precautions: •Upon removal of BLOOD-PACK™ unit from the clear plastic overwrap, visually inspect the unit. •Do not use the product if the in-line cannula is broken and/or anticoagulant is present in the sample pouch or in the tubing from the in-line cannula to the sample pouch and donor needle (see Figure 1). Note that condensation in the empty tubing of the BLOOD-PACK unit is expected as a result of the sterilization process. •Do not use unless the solutions are clear.1.Identify BLOOD-PACK unit using appropriate donor identification system.2.Donor scale. •Adjust donor scale to desired collection weight. •Position primary container on the donor scale as far as possible below donor arm.3.Clamp donor tubing between the needle and Y-junction with hemostat. (This step can be performed prior to step 1 or 2.)4.Visually inspect the tubing from the in-line cannula to the sample pouch and donor needle, as well as the sample pouch to reconfirm that there is no anticoagulant present.Note: Ensure that the sample pouch remains below the donor’s arm.5.Following blood center procedures, apply pressure to donor’s arm and disinfect site of venipuncture.6.Remove needle cover per instructions below: •Holding the hub and cover near the tamper-evident seal, twist cover 1/4 turn to break seal. •Remove needle cover, being careful not to drag the cover across the needle point.7.Following blood center procedures, perform venipuncture, appropriately secure donor needle and/or tubing and release hemostat.8.When good blood flow is established, slide the DONORCARE™ needle guard over the needle hub into the engaged position. Leave the front third of the needle hub exposed for access. Stabilize the front of the needle guard to arm with tape. (see Figure 2)Note: In difficult collection conditions (e.g. slow blood flow), leave the needle guard disengaged behind the hub during collection. Engage the needle guard at the end of blood collection. Appropriately secure needle and/or tubing. 9.Allow the sample pouch to fill with blood according to center procedure. Monitor blood flow into sample pouch.Notes: •The sample pouch contains an average fill volume of approximately 53 mL with a maximum fill volume of approximately 60 mL when filled to capacity. •If less blood sample volume is required, the flow to the sample pouch may be stopped prior to completely filling the pouch. For example, in order to target a fill volume of approximately 40 mL, fill to the level indicated by the arrows in Figure 1. Ensure the pouch is hanging vertically. •The tube leading from the Y-junction to the sample pouch contains an additional volume of approximately 2 mL.Precautions: •Do not elevate or squeeze the sample pouch as this could cause blood to backflow from the sample pouch into the collection system. •Once the sample pouch is filled to desired volume, complete steps 10 - 18 within approximately 4 minutes to avoid possible clot formation in the tubing and/or sample pouch.10.Close the blue clamp on tubing between the Y-junction and the sample pouch.11.Break the in-line cannula below the Y-junction in the donor tubing to the primary container allowing blood collection to proceed. To completely break the in-line cannula, grasp with both hands. Snap it at a 90° angle in one direction, and then bend it at a 90° angle in the opposite direction. Ensure the in-line cannula is completely broken and that the blood flows freely to the primary container.Precaution: Failure to break the in-line cannula completely may result in restricted blood flow.12.Following blood center procedures, mix blood and anticoagulant in the primary container immediately and at several intervals during collection.13.Following blood center procedures, hermetically seal the tubing between the sampling site and the Y-junction to maintain sterility of the blood collection system prior to removing blood samples.Warning: •Do not proceed with the remaining steps until the tubing leading to the sample pouch is hermetically sealed between the sampling site and the Y-junction. To maintain the whole blood collection container as a closed system, the tubing between the sample pouch and Y-junction must be hermetically sealed prior to inserting the access device into the sampling site. Failure to do so may lead to contamination of the whole blood collection.14.Insert the access device by pushing firmly into the sampling site until the membrane seal is penetrated. Note: If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon insertion to avoid barrel detaching from Luer.15.Open the cap on the access device (if applicable). Hold access device so that the sample pouch hangs down.16.Directly align the vacuum sample tube with the internal needle in the access device. Insert vacuum sample tube into device.17.Allow vacuum sample tube to fill with blood then remove from the access device.18.Repeat steps 16 and 17 until the desired number of vacuum sample tubes have been filled.Notes: •If the access device needs to be replaced, use a hemostat to clamp the tubing between the sampling site and the sample pouch. Then, grasp base of sampling site with one hand and pull the access device out with the other hand. Firmly insert the new access device. Remove hemostat and continue sampling. •If the access device is assembled such that the outer barrel is screwed onto the Luer, make sure to rotate clockwise upon removal to avoid barrel detaching from Luer. •The access device can only be replaced one time.Precaution: When replacing access device, be careful to avoid contact with any blood droplets on the Luer or sampling site. Discard used access device appropriately.19.Collect the appropriate volume based on BLOOD-PACK unit used.Note: The volume of anticoagulant is sufficient for the blood collection indicated on BLOOD-PACK unit ± 10%.Precaution: Once the desired blood volume is collected, complete steps 20-23 within approximately 4 minutes to avoid possible clot formation in the tubing.20.Release pressure on the donor’s arm. If appropriate, apply hemostat to donor tubing between the needle and the Y-junction.21.Hermetically seal donor tubing near in-line cannula on side leading to the primary container.22.Withdrawal of Needle (see Figure 3)Precaution: The needle guard must be held stationary while the needle is withdrawn into it.a)Place folded sterile gauze over puncture site and hold in place with finger tip without exerting pressure.b)Hold sides of needle guard near the front, between the index finger and thumb. Pull the tubing smoothly until the needle is locked into the needle guard.c)Confirm the needle lock by: •Listen for the 2nd “click” as the needle is drawn into the needle guard. •Ensure the tubing cannot be pulled through the needle guard.23.Strip blood from donor tubing into primary container, mix and allow the tubing to refill; repeat once. 24.Seal at X marks on donor tubing to provide numbered aliquots of anticoagulated blood for typing or crossmatching. Note: Step 25 may be performed prior to step 23 or 24 if desired.25.Remove and discard the Sample Diversion System and needle guard into an appropriate biohazardous waste container following established procedures.Component Preparation:Notes: •If a platelet concentrate is to be prepared, it should be separated from the red blood cells within 8 hours after blood collection. •Fresh frozen plasma should be separated from the red blood cells and placed in the freezer at -18° C or colder within 8 hours after blood collection.26.When processing a multiple BLOOD-PACK unit, centrifuge primary and secondary containers to prepare CPDA-1 red blood cells. 27.Place primary container in plasma extractor and express plasma into the appropriate empty TransferPack™ container by releasing pressure plate and opening closure in tubing of primary container. 28.When desired amount of plasma has been removed, clamp tubing between Y and plasma container. 29.Seal transfer tubing in three places between the Y-connector and primary container. Cut middle seal being careful to avoid fluid splatter. 30.For further processing with multiple BLOOD-PACK units, use standard component processing and storage techniques.31.Store suspended CPDA-1 whole blood/red blood cells between 1 and 6°C. 32.Infuse CPDA-1 whole blood/red blood cells within 35 days of collection. Warning: Failure to achieve closed system processing conditions negates the extended storage claim and the red blood cell product must be transfused within 24 hours.Store at Controlled Room Temperature.USP Definition of “Controlled Room Temperature”United States Pharmacopeia, General Notices.United States Pharmacopeial Convention, Inc.12601 Twinbrook Parkway, Rockville, MDFenwal, IncLake Zurich, IL 60047 USAMade in USA1-800-933-692507-19-04-631 REV: A 03/2010– ManufacturerFENWAL, Blood-Packand TransferPackare trademarks of Fenwal, Inc.DONORCARE is a trademark of ITL Corporation.© 2010 Fenwal, Inc. All rights reserved.

Package/Label Display Panel

  • Code 4R3629 20 UnitsFenwal™Anticoagulant Citrate Phosphate Dextrose Adenine Solution, USP (CPDA-1) BLOOD-PACK™ UnitTriple For the Collection and Processing of 450 mL BloodSample Diversion System, DONORCARE™ Needle Guard, 16 ga. Ultra Thin Wall NeedleRx onlyEach unit consists of a PL 146 Plastic primary container with 63 mL of CPDA-1 solution containing 2 g Dextrose (monohydrate) USP, 1.66 g Sodium Citrate (dihydrate) USP, 188 mg Citric Acid (anhydrous) USP, 140 mg Monobasic Sodium Phosphate (monohydrate) USP and 17.3 mg Adenine USP, pH may have been adjusted with sodium hydroxide; two empty 400 mL PL 1240 Plastic TRANSFER-PACK™ containers.Sterile, non-pyrogenic fluid path.See instructions for use.Store at Controlled Room Temperature (refer to direction insert). •Open pouch by tearing across at notch. •Direct handling of product surfaces prior to extended storage in the foil pouch, may result in mold growth. •Unused units in open foil pouch may be kept up to 60 days by folding and securing open end of foil pouch to prevent possible loss of moisture, provided:I)Units are not removed from foil pouch, orII)Unused units removed from foil pouch are returned to the foil pouch within 12 hours. Units may be removed from the pouch and returned only once. •Units removed from the foil pouch (that are not returned to the pouch within 12 hours) must be used within 4 days (96 hours). Units out of the foil pouch for longer than 96 hours must be discarded.FENWAL, BLOOD-PACK and TRANSFER-PACK are trademarks of Fenwal, Inc.DONORCARE is a trademark of ITL Corporation.Fenwal, Inc.Lake Zurich, IL 60047 USAMade in USA07-28-05-595 REV: A

* Please review the disclaimer below.